atrophic vaginitis

From Aaushi
Jump to navigation Jump to search

Introduction

also see genitourinary syndrome of menopause

Etiology

Epidemiology

Pathology

* Lactobacillus is estrogen-dependent[5]

Clinical manifestations

Laboratory

Management

* concurrent progestin not needed with low-dose vaginal estrogen since systemic absorption is insufficient to cause endometrial proliferation[1]

More general terms

Additional terms

References

  1. 1.0 1.1 Medical Knowledge Self Assessment Program (MKSAP) 11, 17, 18. American College of Physicians, Philadelphia 1998, 2015, 2018.
  2. 2.0 2.1 2.2 2.3 Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004;
    Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
    Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
    Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  3. Bachmann G, Bouchard C, Hoppe D et al Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009 Jul-Aug;16(4):719-27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19436223
  4. Lynch C. Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health (Larchmt). 2009 Oct;18(10):1595-606 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19788364
  5. 5.0 5.1 5.2 Brotman RM et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause 2014 May; 21:450 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24080849
  6. No authors listed Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23985562
  7. 7.0 7.1 Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016 Oct; 23:1102 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27404032
  8. 8.0 8.1 Mitchell CM, Reed SD, Diem S et al Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms. A Randomized Clinical Trial. JAMA Intern Med. Published online March 19, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29554173 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2674257
  9. 9.0 9.1 FDA Safety Communication. July 31, 2018 FDA Warns Against Use of Energy-Based Devices to Perform Vaginal 'Rejuvenation' or Vaginal Cosmetic Procedures: FDA Safety Communication. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm615013.htm
  10. 10.0 10.1 Lifits-Podorozhansky YM et al Role of vulvar care guidelines in the initial management of vulvar complaints. J Low Genit Tract Dis. 2012;16(2):88-91 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22227837
  11. 11.0 11.1 11.2 North American Menopause Society The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017 Jul;24(7):728-753 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28650869 <Internet> http://www.menopause.org/docs/default-source/2017/nams-2017-hormone-therapy-position-statement.pdf